Emergent BioSolutions, a provider of public health products to government and healthcare providers, agreed to acquire TEMBEXA, a medical countermeasure for smallpox, from Chimerix, a biopharmaceutical company, for $338m. “Emergent is an ideal partner to maximize the long-term potential of TEMBEXA to ensure pandemic preparedness in the event of a smallpox recurrence. This transaction significantly enhances Chimerix’s balance sheet and allows us to focus and invest in our development pipeline. We also continue to participate in the longer-term economics of TEMBEXA through US milestones and double-digit royalties from US and international revenues," Mike Sherman, Chimerix CEO.